A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease

Wajeh Qunibi, Wolfgang C Winkelmayer, Richard Solomon, Moustafa Moustafa, Paul Kessler, Chiang-Hong Ho, Jonathan Greenberg, Jose A Diaz-Buxo, Wajeh Qunibi, Wolfgang C Winkelmayer, Richard Solomon, Moustafa Moustafa, Paul Kessler, Chiang-Hong Ho, Jonathan Greenberg, Jose A Diaz-Buxo

Abstract

Background: Hyperphosphatemia in patients with chronic kidney disease (CKD) contributes to secondary hyperparathyroidism, soft tissue calcification, and increased mortality risk. This trial was conducted to examine the efficacy and safety of calcium acetate in controlling serum phosphorus in pre-dialysis patients with CKD.

Methods: In this randomized, double-blind, placebo-controlled trial, 110 nondialyzed patients from 34 sites with estimated GFR < 30 mL/min/1.73 m² and serum phosphorus > 4.5 mg/dL were randomized to calcium acetate or placebo for 12 weeks. The dose of study drugs was titrated to achieve target serum phosphorus of 2.7-4.5 mg/dL. Serum phosphorus, calcium, iPTH, bicarbonate and serum albumin were measured at baseline and every 2 weeks for the 12 week study period. The primary efficacy endpoint was serum phosphorus at 12 weeks. Secondary endpoints were to measure serum calcium and intact parathyroid hormone (iPTH) levels.

Results: At 12 weeks, serum phosphorus concentration was significantly lower in the calcium acetate group compared to the placebo group (4.4 ± 1.2 mg/dL vs. 5.1 ± 1.4 mg/dL; p = 0.04). The albumin-adjusted serum calcium concentration was significantly higher (9.5 ± 0.8 vs. 8.8 ± 0.8; p < 0.001) and iPTH was significantly lower in the calcium acetate group compared to placebo (150 ± 157 vs. 351 ± 292 pg/mL respectively; p < 0.001). At 12 weeks, the proportions of subjects who had hypocalcemia were 5.4% and 19.5% for the calcium acetate and the placebo groups, respectively, while the proportions of those with hypercalcemia were 13.5% and 0%, respectively. Adverse events did not differ between the treatment groups.

Conclusions: In CKD patients not yet on dialysis, calcium acetate was effective in reducing serum phosphorus and iPTH over a 12 week period.

Trial registration: www.clinicaltrials.gov NCT00211978.

Figures

Figure 1
Figure 1
Patient disposition from screening to end of study.
Figure 2
Figure 2
Serum phosphorus concentration (mg/dL) from randomization to 12 weeks.
Figure 3
Figure 3
Proportion (%) of patients in, below, or above the target range of serum phosphorus concentration (2.7-4.5 mg/dL) at 12 weeks.
Figure 4
Figure 4
Serum calcium concentration (mg/dL) from randomization to 12 weeks.
Figure 5
Figure 5
Proportion (%) of patients in, below, or above the target range of serum calcium concentration (8.5-10.2 mg/dL) at 12 weeks.
Figure 6
Figure 6
Serum intact parathyroid hormone concentration (pg/mL).
Figure 7
Figure 7
Proportion (%) of patients in, below, or above the target range of serum parathyroid hormone level (70-110 pg/mL) at 12 weeks.

References

    1. El Nahas AM, Bello AK. Chronic Kidney Disease: The global challenge. Lancet. 2005;365:331–340.
    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of Chronic Kidney Disease in the United States. JAMA. 2007;298:2038–2047. doi: 10.1001/jama.298.17.2038.
    1. United States Renal Data System. 2000 Annual Data. Bethesda, MD, USA. 2000.
    1. Keith DS, Nichols GA, Gullion CM, Brown JB, Smithet DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–663. doi: 10.1001/archinte.164.6.659.
    1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218. doi: 10.1097/01.ASN.0000133041.27682.A2.
    1. Isakova T, Gutiérrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M. Phosphorus Binders and Survival on Hemodialysis. J Am Soc Nephrol. 2009;20:388–396. doi: 10.1681/ASN.2008060609.
    1. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest. 1995;96:1786–1793. doi: 10.1172/JCI118224.
    1. Qunibi WY. Consequences of hyperphosphatemia. Kidney Int. 2004;66(Suppl 90):8–12. doi: 10.1111/j.1523-1755.2004.09004.x.
    1. Slatopolsky E, Brown A, and Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001;37(Suppl 2):54–57. doi: 10.1053/ajkd.2001.20740.
    1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int. 1999;56(Suppl 73):14–19. doi: 10.1046/j.1523-1755.1999.07304.x.
    1. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW. PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22:2909–2916. doi: 10.1093/ndt/gfm286.
    1. Hruska KA, Teitelbaum SL. Mechanisms of disease: Renal osteodystrophy. N Engl J Med. 1995;333:166–175. doi: 10.1056/NEJM199507203330307.
    1. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol. 2006;1:825–831. doi: 10.2215/CJN.02101205.
    1. Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Kidney Disease: Improving Global Outcomes (KDIGO) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2006;69:1945–1953. doi: 10.1038/sj.ki.5000414.
    1. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum Phosphorus Levels Associate with Coronary Atherosclerosis in Young Adults. J Am Soc Nephrol. 2009;20:397–404. doi: 10.1681/ASN.2008020141.
    1. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–E17.
    1. Kestenbaum BR, Adeney KL, de Boer IH, Ix JH, Shlipak MG, Siscovick DS. Incidence and progression of coronary calcification in chronic kidney disease: The Multi-Ethnic Study of Atherosclerosis. Kidney Int. 2009;76:991–998. doi: 10.1038/ki.2009.298.
    1. Mathew S, Tustison KS, Sugatani T, Chaudhary LR, Rifas L, Hruska KA. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008;19:1092–1105. doi: 10.1681/ASN.2007070760.
    1. Qunibi WY. Cardiovascular calcification in nondialyzed patients with chronic kidney disease. Semin Dial. 2007;20:134–8. doi: 10.1111/j.1525-139X.2007.00260.x.
    1. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857–2867. doi: 10.1097/01.ASN.0000141960.01035.28.
    1. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis. 2004;44:1024–1030. doi: 10.1053/j.ajkd.2004.07.022.
    1. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16:520–528. doi: 10.1681/ASN.2004070602.
    1. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879–885. doi: 10.1001/archinte.167.9.879.
    1. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl):1–201.
    1. Sirmon MD, Kirpatrick WG, Nolan CR, Schmitt GW, Cleveland MB. Calcium acetate control of phosphorus in hemodialysis patients. Am J Kidney Dis. 1991;17:544–550.
    1. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, Pelham RW, Cleveland MV, Muenz LR, He DY, Nolan CR. Treatment of hyperphosphatemia in hemodialysis patients: The calcium acetate Renagel Evaluation (CARE Study) Kidney Int. 2004;65:1914–1926. doi: 10.1111/j.1523-1755.2004.00590.x.
    1. Wallot M, Bonzel KE, Winter A, Georger B, Lettgen B, Bald M. Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol. 1996;10:625–30. doi: 10.1007/s004670050175.
    1. Kalantar-Zadeh K, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial. 2004;17:455–465. doi: 10.1111/j.0894-0959.2004.17606.x.
    1. Kraut JA. The role of metabolic acidosis in the pathogenesis of renal osteodystrophy. Adv Ren Replace Ther. 1995;2:40–51.
    1. Borrego J, Pérez del Barrio P, Serrano P, García Cortés MJ, Sánchez Perales MC, Borrego FJ, Liébana A, Gil Cunquero JM, Pérez Bañasco V. A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis. Nefrologia. 2000;20:348–54.
    1. Ketteler M, Rix M, Fan S, Pritchard N, Oestergaard O, Chasan-Taber S, Heaton J, Duggal A, Kalra PA. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol. 2008;3:1125–1130. doi: 10.2215/CJN.05161107.
    1. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4: A Randomized Trial. Clin J Am Soc Nephrol. 2009;4:178–185. doi: 10.2215/CJN.02830608.
    1. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255–1261. doi: 10.1038/sj.ki.5002518.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa